V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004857 | 10009127 | 1.79 | 0 | null | 2014-09-24 | 2014-10-09 | TUXEDO TRIAL | 02 | N | 10548878 | NIVOLUMAB |
| 10004858 | 10003041 | 1.72 | 87 | null | 2015-10-08 | 2015-10-14 | IPILIMUMAB + NIVOLUMAB | N | Y | 10548958 | PAD |
| 10004859 | 10003042 | 1.59 | 56.7 | Palliative (P) | 2018-09-02 | 2018-09-02 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 10548972 | CHOEP |
| 10004860 | 10003043 | 1.62 | 102 | Palliative (P) | 2017-07-17 | 2017-07-17 | Capecitabine + Streptozocin | N | N | 10548978 | MIC |
| 10004861 | 10003043 | 1.77 | 78 | Curative (C) | 2014-03-30 | 2014-03-30 | Dacarbazine | N | null | 10548978 | TEMOZOLOMIDE |
| 10004862 | 10003043 | null | 117 | Curative (C) | 2016-11-28 | 2016-11-28 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10548978 | CARBOPLATIN + RT |
| 10004863 | 10003044 | 1.84 | 82.4 | Palliative (P) | 2016-08-16 | 2016-08-22 | LOPP | 2 | N | 10549126 | BORTEZOMIB + THALIDOMIDE |
| 10004864 | 10003045 | null | 82.3 | Disease modification (D) | 2017-02-07 | 2017-02-26 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | N | 10549143 | GEFITINIB |
| 10004865 | 10003045 | null | 70.6 | Palliative (P) | 2018-08-29 | 2018-09-15 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 2 | null | 10549143 | TRASTUZUMAB |
| 10004866 | 10008232 | 1.75 | null | Palliative (P) | 2016-11-19 | 2016-11-28 | Gemcitabine+Paclitaxel (Neo-tAnGo) | null | N | 10549203 | AFATINIB |
| 10004867 | 10006740 | null | null | Palliative (P) | 2015-12-23 | 2015-12-25 | IPILIMUMAB + NIVOLUMAB | N | N | 10549221 | RUXOLITINIB |
| 10004868 | 10006740 | 1.53 | 52.5 | Palliative (P) | 2017-03-25 | 2017-03-25 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 10549221 | CETUXIMAB + IRINOTECAN + MDG |
| 10004869 | 10003046 | 1.82 | null | Palliative (P) | 2017-08-27 | 2017-08-30 | CARBOPLATIN + FLUOROURACIL + Trastuzumab | 02 | N | 10549275 | CYTARABINE |
| 10004870 | 10003047 | 1.82 | 91.6 | Curative (C) | null | 2017-06-13 | Capecitabine + Cisplatin + RT | 02 | N | 10549295 | INCA TRIAL |
| 10004871 | 10003047 | 1.71 | 67.6 | Palliative (P) | 2017-04-24 | 2017-04-27 | CHLVPP | N | N | 10549295 | VINORELBINE |
| 10004872 | 10003048 | 1.69 | 80.5 | Palliative (P) | 2018-02-23 | 2018-02-27 | Gemcitabine+Paclitaxel (Neo-tAnGo) | 02 | N | 10549592 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004873 | 10003049 | 1.71 | 85.4 | Disease modification (D) | 2014-03-31 | 2014-04-14 | CARBOPLATIN + RT | N | N | 10549637 | BORTEZOMIB + THALIDOMIDE |
| 10004874 | 10003050 | 1.7 | 93.25 | Disease modification (D) | 2016-06-24 | 2016-06-24 | BALLAD Trial | N | null | 10549676 | STAMPEDE TRIAL |
| 10004875 | 10003051 | 1.72 | 62.2 | null | 2014-06-30 | 2014-07-09 | Folfirinox | N | N | 10549795 | VINCRISTINE |
| 10004876 | 10003052 | 1.76 | 91.6 | Palliative (P) | 2018-08-17 | 2018-08-17 | Bortezomib + MELPHALAN | N | N | 10549872 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10004877 | 10003052 | 1.73 | 94 | Disease modification (D) | 2015-09-01 | 2015-09-03 | VISMODEGIB | 2 | N | 10549872 | GEFITINIB |
| 10004878 | 10003052 | null | 53.45 | Palliative (P) | 2017-11-15 | 2017-11-18 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | N | 10549872 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004879 | 10003052 | 1.72 | 86.8 | null | 2018-04-30 | 2018-05-20 | PAM x 2 post-surgery (cycles 3&4) | 02 | N | 10549872 | CAPECITABINE + MITOMYCIN |
| 10004880 | 10003053 | 1.7 | 84.7 | Unknown (U) | 2017-07-24 | 2017-07-24 | R Chlorambucil | N | N | 10550086 | SORAFENIB |
| 10004881 | 10003054 | 1.68 | 107.9 | Disease modification (D) | 2018-06-06 | 2018-06-14 | Doxorubicin + Olaratumab | N | N | 10550104 | CYTARABINE |
| 10004882 | 10006743 | 1.77 | null | Curative (C) | 2018-03-29 | 2018-03-29 | IRINOTECAN + MDG + PANITUMUMAB | N | N | 10550149 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10004883 | 10006743 | 1.6 | 107 | Palliative (P) | 2015-04-16 | 2015-04-17 | DA-EPOCH-R | N | N | 10550149 | CLARITY TRIAL |
| 10004884 | 10003055 | null | 55 | Palliative (P) | 2017-04-17 | 2017-05-01 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINBLASTINE | 02 | N | 10550166 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004885 | 10003056 | 0 | 102 | Curative (C) | 2018-08-21 | 2018-08-21 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | N | N | 10550284 | CLARITY TRIAL |
| 10004886 | 10003057 | 1.73 | 101.45 | null | 2018-08-15 | 2018-08-15 | Ipilimumab | N | N | 10550349 | CISPLATIN + FLUOROURACIL |
| 10004887 | 10003058 | 1.7 | 69.8 | Palliative (P) | 2017-05-31 | 2017-05-31 | Vemurafenib | 02 | N | 10550378 | CISPLATIN + DOCETAXEL |
| 10004888 | 10003059 | 1.82 | 0 | Curative (C) | 2019-02-15 | 2019-02-25 | AXITINIB | 02 | N | 10550395 | SUNITINIB |
| 10004889 | 10003060 | 1.76 | null | Adjuvant (A) | 2016-04-15 | 2016-05-17 | CAPECITABINE + MITOMYCIN + RT | N | N | 10550423 | CLADRIBINE |
| 10004890 | 10003060 | 1.71 | 91.2 | Neo-adjuvant (N) | 2014-10-23 | 2014-11-19 | MPT | null | Y | 10550423 | CHLORAMBUCIL + RITUXIMAB |
| 10004891 | 10003061 | 1.73 | null | Palliative (P) | 2017-11-30 | 2017-12-04 | Bortezomib + MELPHALAN | 02 | N | 10550478 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10004892 | 10003062 | 1.63 | 108 | Palliative (P) | 2015-02-10 | 2015-02-10 | Pemetrexed | 02 | N | 10550504 | AFATINIB |
| 10004893 | 10003062 | 1.59 | 55.1 | Palliative (P) | null | 2018-05-30 | VINORELBINE | N | null | 10550504 | ERLOTINIB |
| 10004894 | 10003062 | 1.61 | 85 | Palliative (P) | 2018-09-01 | 2018-09-01 | Erlotinib | N | N | 10550504 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004895 | 10003063 | 0 | 92 | Disease modification (D) | 2017-02-02 | 2017-02-02 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10550571 | BORTEZOMIB + THALIDOMIDE |
| 10004896 | 10003064 | 1.83 | null | Curative (C) | 2017-04-30 | 2017-05-13 | IBRUTINIB | 02 | Y | 10550604 | IBRUTINIB |
| 10004897 | 10003065 | 1.74 | 75.4 | Palliative (P) | 2017-01-20 | 2017-02-10 | CARBOPLATIN + PACLITAXEL + RT | 02 | N | 10550612 | CETUXIMAB + IRINOTECAN + MDG |
| 10004898 | 10003066 | 1.77 | null | Palliative (P) | 2018-08-01 | 2018-08-04 | ECarboX | 02 | N | 10550639 | RUXOLITINIB |
| 10004899 | 10006746 | 1.66 | 64 | Disease modification (D) | 2017-10-12 | 2017-10-17 | DABRAFENIB + TRAMETINIB | Y | N | 10551005 | VINCRISTINE |
| 10004900 | 10003067 | 1.62 | 0 | Palliative (P) | 2018-03-31 | 2018-04-28 | Folfirinox | null | N | 10551030 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004901 | 10003068 | null | 67.8 | Curative (C) | 2018-03-30 | 2018-03-30 | Cetuximab + CISPLATIN + FLUOROURACIL | 02 | N | 10551093 | CHLORAMBUCIL + RITUXIMAB |
| 10004902 | 10003069 | 1.67 | 59.9 | Disease modification (D) | 2014-04-03 | 2014-04-17 | Cisplatin + Doxorubicin | N | N | 10551135 | PANITUMUMAB |
| 10004903 | 10003070 | 1.54 | 0 | Disease modification (D) | 2017-05-03 | 2017-05-05 | MPV (cycle 1-4) | 02 | N | 10551288 | CAPECITABINE + CISPLATIN + STREPTOZOCIN |
| 10004904 | 10003071 | 1.82 | 100 | Neo-adjuvant (N) | 2017-08-06 | 2017-08-26 | Carboplatin + Docetaxel | 02 | N | 10551303 | BENDAMUSTINE + THALIDOMIDE |
| 10004905 | 10006747 | 1.73 | null | Palliative (P) | 2018-03-30 | 2018-03-30 | Doxorubicin chemoembolisation | null | N | 10551376 | SUNITINIB |
| 10004906 | 10008237 | null | 92.35 | Adjuvant (A) | 2017-12-28 | 2018-01-07 | BORTEZOMIB + THALIDOMIDE | 02 | N | 10551377 | BORTEZOMIB + THALIDOMIDE |